Perfil
James Moodie Rae is the founder of Remedies Health Care Services, Inc. He is currently the President, Chief Executive Officer & Director at Viron Therapeutics, Inc. and also holds a position as a Director at Cita NeuroPharmaceuticals, Inc. In the past, he served as the President & Chief Executive Officer at Cangene Corp.
from 1988 to 1996.
He was also the Chief Executive Officer at Cytochroma, Inc. and held the positions of Chairman & Chief Executive Officer at Vaxis Therapeutics Corp and Resolution Pharmaceuticals, Inc. Additionally, he served as the Independent Chairman at Telesta Therapeutics, Inc. in 2012.
From 2007 to 2011, he was the Chairman at Aegera Therapeutics, Inc. and also held the position of Chairman at Receptor Therapeutics, Inc. He served as a Director at Arius Research, Inc. from 2007 to 2008 and is currently a Director at PlantForm Corp.
Cargos activos de James Moodie Rae
| Empresas | Cargo | Inicio |
|---|---|---|
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Director/Miembro de la Junta | - |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Director Ejecutivo | 01/01/2007 |
| Remedies Health Care Services, Inc. | Fundador | - |
Antiguos cargos conocidos de James Moodie Rae.
| Empresas | Cargo | Fin |
|---|---|---|
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Presidente | - |
Arius Research, Inc.
 Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Director/Miembro de la Junta | 24/09/2008 |
| CANGENE CORPORATION | Director Ejecutivo | 02/01/1996 |
PlantForm Corp.
 PlantForm Corp. Pharmaceuticals: MajorHealth Technology PlantForm Corp. engages in a biopharmaceutical company. It focuses on the development and production of ntibody and protein drugs using manufacturing platform. The firm’s vivoXPRESS technology uses genetically modified tobacco plants to produce biopharmaceuticals in fully contained greenhouse environments. The company was founded by J. Christopher Hall, Mark Goldberg, Don Stewart, and Ronald G. Hosking in 2008 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | - |
| TELESTA THERAPEUTICS INC | Presidente | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 12 |
|---|---|
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | Health Technology |
Cangene Corp.
 Cangene Corp. Pharmaceuticals: MajorHealth Technology Cangene Corp. developed, manufactured and sold biopharmaceutical drugs. The company was founded on February 22, 1984 and was headquartered in Winnipeg, Canada. | Health Technology |
Cita NeuroPharmaceuticals, Inc.
Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Health Technology |
Cytochroma, Inc.
 Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada. | Health Technology |
Vaxis Therapeutics Corp
 Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Part of DMK Pharmaceuticals Corp., Vaxis Therapeutics Corp manufactures and researches pharmaceutical products. The company is based in Kingston, Canada. Vaxis Therapeutics was acquired by Cellegy Pharmaceuticals, Inc. on November 29, 2001 for $4 million. | Health Technology |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
| Resolution Pharmaceuticals, Inc. | |
Receptor Therapeutics, Inc.
 Receptor Therapeutics, Inc. BiotechnologyHealth Technology Receptor Therapeutics, Inc. was a bio-pharmaceutical company focused on in-licensing and developing anti-cancer therapies. The company was founded in 2007 and was headquartered in Toronto, Canada. | Health Technology |
PlantForm Corp.
PlantForm Corp. Pharmaceuticals: MajorHealth Technology PlantForm Corp. engages in a biopharmaceutical company. It focuses on the development and production of ntibody and protein drugs using manufacturing platform. The firm’s vivoXPRESS technology uses genetically modified tobacco plants to produce biopharmaceuticals in fully contained greenhouse environments. The company was founded by J. Christopher Hall, Mark Goldberg, Don Stewart, and Ronald G. Hosking in 2008 and is headquartered in Toronto, Canada. | Health Technology |
| Remedies Health Care Services, Inc. |
- Bolsa de valores
- Insiders
- James Moodie Rae
